News

Regulatory affairsRegulatory Round-up - July 2026
Filter:AllPress ReleaseCell TherapiesGene TherapiesDigital and AutomationSpin-outs, Start-ups, Sector investmentManufacturingRegulatory affairsSkills and Training
Year:All2026202520242023 →
Growth in UK cell and gene therapy manufacturing capacity and employment continuesGrowth in UK cell and gene therapy manufacturing capacity and employment continuesCell and Gene Therapy Catapult recognised for two HR industry awardsCell and Gene Therapy Catapult recognised for two HR industry awardsRegulatory Round-up - October 2022Regulatory Round-up - October 2022Cell and Gene Therapy Catapult at Advanced Therapies Integrates: A Bird’s Eye BlogCell and Gene Therapy Catapult at Advanced Therapies Integrates: A Bird’s Eye BlogCharles River Laboratories opens cutting-edge cell and gene therapy manufacturing facility at Alderley ParkCharles River Laboratories opens cutting-edge cell and gene therapy manufacturing facility at Alderley ParkCGT Catapult named as a Finalist in the British Recruitment Awards 2022CGT Catapult named as a Finalist in the British Recruitment Awards 2022London Laboratory and GMP Manufacturing Roundtable White PaperLondon Laboratory and GMP Manufacturing Roundtable White PaperRegulatory Round-up - September 2022Regulatory Round-up - September 2022Potential to accelerate development in ATMP space demonstrated by ATTC Network partnerPotential to accelerate development in ATMP space demonstrated by ATTC Network partnerCell & Gene Therapy Catapult at Advanced Therapies Europe 2022: A Bird’s Eye BlogCell & Gene Therapy Catapult at Advanced Therapies Europe 2022: A Bird’s Eye BlogAchieve commercial success: the value of a sound manufacturing strategyAchieve commercial success: the value of a sound manufacturing strategyPress Release: Terumo Blood and Cell Technologies launches Quantum Flex bioreactor platform to enable cell therapy commercialisationPress Release: Terumo Blood and Cell Technologies launches Quantum Flex bioreactor platform to enable cell therapy commercialisation